Several clinical trials are evaluating additional agents in patients with SM, including the interleukin 2-diphtheria toxin fusion protein denileukin diftitox and the mechanistic target of rapamycin (mTOR) inhibitor everolimus (US National Institutes of Health 2015). Here, MTOR is linked to systemic mastocytosis.